Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDCX101 (canakinumab)
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Topical
01
Overview
MDCX101 is a topical gel formulation of canakinumab, a human monoclonal antibody that acts as a potent and selective inhibitor of interleukin-1 beta (IL-1β). Developed by researchers at the University of Auckland (UniServices), MDCX101 is specifically designed for the treatment of tophaceous gout, a chronic condition characterized by the accumulation of monosodium urate crystals (tophi) in joints and soft tissues. By delivering canakinumab topically, the treatment aims to neutralize IL-1β locally within the tophus environment, thereby reducing the chronic inflammation that drives tophus formation and potentially promoting the resolution of these deposits. This localized approach is intended to provide therapeutic benefits while minimizing the systemic side effects associated with parenteral IL-1 inhibition. The drug has been evaluated in clinical trials to assess its efficacy in reducing tophus size and improving clinical outcomes in patients with advanced gout.
- Brand names
- Ilaris
- Other names
- MDCX101 GelMDCX-101 GelMDCX 101 Geltopical canakinumab
02
Targets
IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on MDCX101 (canakinumab).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDCX101 (canakinumab).